Context The number of reported cases with SARS-CoV-2 vaccine-induced subacute thyroiditis (SAT) and Graves' disease (GD) is growing. However, active debate continues about managing such side effects and the safety of repeat or booster doses of the vaccines in such cases. Objectives This study aims to present long-term clinical follow-up of SARS-CoV-2 vaccine-induced SAT or GD cases and provide data regarding the safety of re-vaccinations. Methods Patients diagnosed with SARS-CoV-2 vaccine-induced SAT or GD were included. Data regarding the long-term clinical follow-up of SARS-CoV-2 vaccine-induced SAT, and GD cases and outcomes of repeat or booster SARS-CoV-2 vaccinations were documented. The literature, including cases of SARS-CoV-2 vaccine-induced SAT or GD, was reviewed. Results Fifteen patients with SARS-CoV-2 vaccine-induced SAT and four with GD were included. Pfizer/BioNTech COVID-19 vaccine (BNT162b2) was associated with symptoms in a majority of cases with SAT and all with GD. Median time from vaccination to symptom onset was seven and 11.5 days, while seven and two patients required medical treatment in SAT and GD groups, respectively. Remission was documented in ten SAT patients, with a median time to remission of 11.5 weeks. No exacerbation/recurrence of SAT occurred in seven of nine patients who received a repeat vaccination dose, while symptoms of SAT worsened following the second vaccination in two cases. None of the patients has experienced severe side effects that could be associated with re-vaccinations. Conclusions Re-vaccinations appear to be safe in patients with SARS-CoV-2 vaccine-induced SAT cases, while more evidence is needed regarding SARS-CoV-2 vaccine-induced GD.

No abstract

No abstract

No abstract

No abstract